![]() |
| AstraZeneca logo -Supporting patient matching and research |
The project supports research on hypertension in partnership with the UAE-based healthcare company M42.
AstraZeneca has announced a collaboration with Oracle to leverage artificial intelligence (AI) and real-world data to identify suitable patients for clinical trials and monitor safety indicators, as the pharmaceutical company seeks to advance its clinical research efforts.
AstraZeneca stated that this partnership will combine its expertise in drug development with Oracle’s capabilities in AI and healthcare data to facilitate patient matching and research.
The initial project will support hypertension research in Abu Dhabi, in collaboration with the UAE-based healthcare company M42. Patient recruitment remains one of the greatest challenges in clinical research; delays in enrollment often extend the duration of trials and increase development costs.
According to Reuters, the initiative will initially focus on oncology, cardiovascular diseases, respiratory conditions, immunology, and rare diseases, and may also support the early diagnosis of serious illnesses.
In the past, flawed trial protocols have posed challenges for AstraZeneca, with delays in the development of a breast cancer drug and a treatment for neurological disorders raising concerns.
AstraZeneca is seeking to expand its drug portfolio, with a target of achieving annual revenues exceeding $80 billion by 2030, while working to address the obstacles facing the pharmaceutical industry in the field of drug development.

No comments:
Post a Comment